Subcutaneous · GLP-1 / glucagon dual
DD01
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
0
Recruiting
0
Completed
2
Sites
16
Countries
2
Endpoints
45
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
29
MASH / liver
7
Cardiometabolic biomarkers
4
Other (unclassified)
4
Glycemic / diabetes
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Liver fat content, changeMASH
2
MRI-PDFF ≥30% respondersMASH
1
Liver stiffness (VCTE), changeMASH
1
Treatment-emergent AEs (any)Safety/PK
1
Plasma concentration (steady state)Safety/PK
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06410924A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH | DD01 MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 12 | May 2025 | — | |
| NCT04812262A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD | DD01 MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 1 | Completed | 4 | Dec 2022 | — |